Clozapine-induced late leukopenia.

Area of Science:

• Psychiatry
• Pharmacology
• Hematology

Background:

• Schizophrenia treatment often involves a trial of multiple antipsychotic medications.
• Clozapine is a third-generation antipsychotic reserved for treatment-resistant cases.
• Patient presented with a 28-year history of schizophrenia, refractory to numerous treatments.

Observation:

• The patient experienced significant improvement in psychotic symptoms, self-care, and overall well-being with clozapine.
• Treatment with clozapine was successful for six years.
• Leukopenia, a serious adverse effect, developed during clozapine therapy, necessitating its discontinuation.

Findings:

• This case highlights the efficacy of clozapine in treatment-resistant schizophrenia.
• The development of leukopenia presents a significant challenge for continued clozapine use.
• Discussion includes strategies for clozapine rechallenge and management of blood dyscrasias with alternative antipsychotics.

Implications:

• Careful consideration of risk-benefit is crucial when managing clozapine-induced leukopenia.
• Hematological monitoring is essential for patients on clozapine and other antipsychotics.
• This case informs clinical decision-making regarding antipsychotic selection and monitoring in complex schizophrenia cases.